|Dr. Michelle Dipp M.D., Ph.D.||Co-Founder, Exec. Chairman, Acting Pres & Corp. Sec.||830.41k||N/A||41|
|Dr. Jonathan L. Tilly Ph.D.||Co-Founder and Advisor||N/A||N/A||54|
|Mr. Jonathan Gillis||Principal Financial Officer, Principal Accounting Officer & VP of Fin.||N/A||N/A||N/A|
|Cara Mayfield||Director of Corp. Communications||N/A||N/A||N/A|
|Dr. Gabriel M. Cohn M.D.||Head of Global Clinical & Medical Affairs and VP||N/A||N/A||N/A|
OvaScience, Inc., a fertility company, discovers, develops, and commercializes fertility treatment options for women worldwide. The companys patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman's own ovaries. It engages in developing and commercializing various fertility treatment options designed to enhance egg health and revolutionize the fertility treatment consisting of AUGMENT to enhance the energy and health of the womans eggs by using mitochondria from a woman's EggPC cells; OvaTure to produce mature fertilizable eggs from a womans own EggPC cells without the need for hormone injections; OvaPrime treatment is used to replenish a woman's egg reserve by transferring the EggPCs from woman's own ovaries; and OvaXon for the prevention of inherited human disease and improvement of animal health. The company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011. OvaScience, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
OvaScience, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 9. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 10.